Q2 EPS Estimates for MiMedx Group Cut by Northland Capmk

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Northland Capmk decreased their Q2 2025 earnings per share estimates for shares of MiMedx Group in a report released on Thursday, May 1st. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.06 per share for the quarter, down from their previous estimate of $0.07. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share.

MDXG has been the topic of several other research reports. StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

MiMedx Group Stock Down 3.6 %

MDXG stock traded down $0.27 during mid-day trading on Monday, hitting $7.15. 295,905 shares of the company were exchanged, compared to its average volume of 691,613. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm's 50 day simple moving average is $7.30 and its 200 day simple moving average is $8.10. The firm has a market cap of $1.06 billion, a P/E ratio of 13.00 and a beta of 1.85.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $88.21 million for the quarter, compared to the consensus estimate of $86.32 million.

Hedge Funds Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently modified their holdings of the company. IMG Wealth Management Inc. bought a new position in MiMedx Group in the fourth quarter valued at about $28,000. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group in the 4th quarter worth approximately $35,000. Van ECK Associates Corp bought a new position in shares of MiMedx Group in the 4th quarter worth approximately $40,000. Tower Research Capital LLC TRC boosted its holdings in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after buying an additional 2,837 shares during the last quarter. Finally, AlphaQuest LLC bought a new stake in MiMedx Group during the fourth quarter valued at approximately $88,000. 79.15% of the stock is owned by institutional investors.

Insider Buying and Selling at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 81,446 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the completion of the transaction, the chief accounting officer now directly owns 494,774 shares in the company, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph H. Capper purchased 200,000 shares of MiMedx Group stock in a transaction dated Friday, May 2nd. The shares were purchased at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the transaction, the chief executive officer now directly owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 144,018 shares of company stock valued at $1,130,312 in the last 90 days. 1.30% of the stock is currently owned by company insiders.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.